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ABSTRACT
Pleckstrin homology-like domain family A member 2 (PHLDA2) is a
maternally expressed imprinted gene whose elevated expression has
been linked to fetal growth restriction in a number of human studies.
In mice, Phlda2 negatively regulates placental growth and limits the
accumulation of placental glycogen. We previously reported that a
three-copy transgene spanning the Phlda2 locus drove a fetal growth
restriction phenotype late in gestation, suggesting a causative role for
PHLDA2 in human growth restriction. However, in this mouse model,
Phlda2 was overexpressed by fourfold, alongside overexpression of
a second imprinted gene, Slc22a18. Here, we genetically isolate the
role of Phlda2 in driving late fetal growth restriction in mice. We
furthermore show that this Phlda2-driven growth restriction is
asymmetrical, with a relative sparing of the brain, followed by rapid
catch-up growth after birth, classic features of placental insufficiency.
Strikingly, fetal growth restriction showed strain-specific differences,
being apparent on the 129S2/SvHsd (129) genetic background and
absent on the C57BL6 (BL6) background. A key difference between
these two strains is the placenta. Specifically, BL6 placentae possess
a more extensive endocrine compartment and substantially greater
stores of placental glycogen. Taken together, these data support a
direct role for elevated Phlda2 in limiting fetal growth but also suggest
that growth restriction only manifests when there is limited placental
reserve. These findings should be taken into account in interpreting
the results from human studies.
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INTRODUCTION
Low birth weight (LBW) is one of the most problematic conditions
affecting human populations. It is a very common complication of
pregnancy, affecting up to 19% of all births in the developing world
and between 5 and 7% of births in developed countries (Valero de
Bernabe et al., 2004). Either as a consequence of poor growth in
utero, preterm birth or a genetic abnormality, some babies are born
too small and are consequently more vulnerable to complications at
the time of birth, with increased risk of mortality (Witt et al., 2012).
Furthermore, it is increasingly recognised that, although these
vulnerable babies can gain weight and seem to recover from their
poor start in life, many will experience complications in later life,
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including alterations in behaviour (ADHD, depression) and
metabolism (obesity, type 2 diabetes, heart disease) (Grissom and
Reyes, 2013). Identifying the molecular origins of growth restriction
is crucial in identifying the most appropriate management of LBW
infants to ensure optimal short- and long-term health outcomes.
Genomic imprinting is an epigenetic phenomenon that drives the
preferential expression of certain genes from one parental allele
(John and Surani, 1996). In humans, a number of childhood growth
disorders, including Beckwith-Wiedemann syndrome (BWS; MIM
#130650) and Silver-Russell syndrome (SRS; MIM #180860),
involve the aberrant expression of imprinted genes (Chiesa et al.,
2012). These imprinting disorders are rare at 1 in 13,000 and 1 in
300,000 births, respectively. However, numerous imprinted genes
play a key role in regulating fetal growth and placental development
in a dosage-sensitive manner, with paternal silencing primarily of
growth-restricting genes and maternal silencing of growth-
promoting genes (Tunster et al., 2013), which suggests that aberrant
imprinting might underlie more common human growth disorders.
Pleckstrin homology-like domain family A member 2 (PHLDA2)
was first highlighted as a potential fetal growth restriction gene in a
2006 study that reported elevated expression in the placenta of 9 out
of the 38 fetal growth restriction (FGR) placentae (McMinn et al.,
2006). Subsequently, several studies have examined PHLDA2 in
relation to fetal growth and birth weight (Jensen et al., 2014).
Whereas some of these studies have supported a role for elevated
PHLDA2 in LBW (Apostolidou et al., 2007; Guo et al., 2008; Lim
et al., 2012), others did not find a clear correlation with birth weight
(Lambertini et al., 2012; Lewis et al., 2012).
We previously reported on a growth restriction phenotype in mice
that was linked to the presence of three copies of a bacterial artificial
chromosome (BAC) spanning the murine Phlda2 locus and a second
imprinted gene, solute carrier family 22, member 18 (Slc22a18) (Salas
et al., 2004; Tunster et al., 2010). Transgenic fetuses were 13% lighter
than control littermates late in gestation, with significant placental
stunting phenotype and a severe loss of placental glycogen. However,
these studies did not establish a direct link between elevated Phlda2
expression and fetal growth restriction, nor did they model the more
subtle elevations in expression reported in human studies. Here, we
sought to clarify the role of the Phlda2 gene in regulating fetal growth
by using transgenic mice carrying a single-copy transgene. We report
that as little as twofold increased expression of Phlda2 was sufficient
to reduce birth weight by 10%. Importantly, growth restriction was
asymmetric, with relative sparing of the brain, followed by rapid
catch-up growth after birth, classic features of placental insufficiency.
RESULTS
In our previous paper, gene expression analysis of a newly generated
BAC transgenic line on mixed genetic background suggested the
presence of at least two copies of the BAC transgene (Tunster et al.,
2010). However, when we bred this line fully into the 129S2/SvHsd
(129) genetic background (>eight generations) and re-examined
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gene expression, the data was more consistent with the presence of
a single copy (Fig. 1A). When we examined fetal weight in the
context of twofold gene expression, growth restriction of
Phlda2+/+BACx1 fetuses was apparent at embryonic day 18.5 (E18.5;
1184.4±8.7 mg versus 1073.8±18.5 mg, P=5.33×10−6) but not at
E14.5 or E16.5 (Fig. 1B), similar to the growth profile we reported
in response to fourfold expression (Tunster et al., 2010). Transgenic
placentae were 10-20% lighter than non-transgenic placentae at each
time point (Fig. 1C), similar to the weight reduction we reported for
a single-copy transgenic line spanning Phlda2, Slc22a18 and
Cdkn1c (Tunster et al., 2010).
To formally test whether the line carried a single copy of the
transgene, we crossed males carrying the BAC with females
carrying a paternally inherited targeted allele of Phlda2, also bred
for >eight generations into the 129 genetic background. This cross
generated four genotypes: Phlda2+/+(129) (one active copy of Phlda2
and Slc22a18), Phlda2+/+BACx1(129) (two active copies Phlda2 and
Slc22a18), Phlda2–/+(129) (maternal-knockout Phlda2, equivalent to
loss of function) and Phlda2–/+BACx1(129) (double transgenic; one
active copy of Phlda2 and two active copies of Slc22a18). At E14.5,
Phlda2 was expressed at wild-type levels in double-transgenic
fetuses, whereas Slc22a18 remained elevated, confirming that the
line carried a single extra copy of Phlda2 (Fig. 2A). Importantly,
these double-transgenic fetuses exposed to a single dose of Phlda2
and a double dose of Slc22a18 were not significantly different in
weight to controls at E18.5 (1123.3±13.8 mg versus
1144.3±23.4 mg, P=0.415; Fig. 2B), whereas fetuses carrying the
single-copy BAC transgene, exposed to a double dose of both genes
(Phlda2+/+BACx1(129)), weighed less than controls (1123.3±13.8 mg
versus 1038.7±23.4 mg, P=0.00180; Fig. 2B). This finding
genetically assigned growth restriction to the twofold-elevated
Phlda2 expression. As observed with a different single-copy BAC
transgene (Tunster et al., 2010), normalising the dose of Phlda2 also
returned placental weights to normal (Fig. 2C).
Loss of function of Phlda2 has previously been characterised on
the C57BL/6 genetic background (Frank et al., 2002; Salas et al.,
2004). We similarly observed substantial placental overgrowth on
the 129 background. Phlda2–/+(129) placentae weighed 33% more
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TRANSLATIONAL IMPACT
Clinical issue
Low birth weight is one of the most intractable and yet clinically relevant
complications affecting human pregnancies. Being born small increases
the risk of complications at the time of birth and can lead to early
mortality. In addition, although low-birth-weight babies often gain weight
and seem to recover from their poor start in life, babies with accelerated
postnatal weight gain after in utero growth restriction have a greatly
increased risk of developing type 2 diabetes, obesity and cardiovascular
disease in later life compared with normal-birth-weight babies. Although
the causes of low birth weight are numerous and include both genetic
and environmental factors, elevated placental expression of the imprinted
gene PHLDA2 has been reported in a number of studies on low birth
weight. However, because correlation does not always equal causation,
determination of the relevance of elevated PHLDA2 expression using an
animal model is of crucial importance.
Results 
In this study, the authors generated a mouse model in which Phlda2
expression was elevated twofold, a similar increase in expression to that
reported in human studies. The authors observed late fetal growth
restriction in the transgenic mice, with the pups being born with a low
birth weight. Crucially, growth restriction was asymmetric, with relative
sparing of the brain, followed by rapid catch-up growth after birth, which
are classic features of placental insufficiency. Moreover, growth
restriction showed strain-specific differences and the effects of Phlda2
overexpression were only apparent in mouse strains in which the
placenta was already working at maximum capacity. 
Implications and future directions
These findings support a causal role for elevated PHLDA2 in the
aetiology of human low birth weight. Moreover, the observation of both
asymmetrical growth restriction and rapid catch-up growth in this new
mouse model of Phlda2 overexpression suggests that human infants
born with a low birth weight owing to this specific alteration might be at
higher risk of later-life health complications than infants born with a low
birth weight for other reasons. This possibility can be investigated by re-
examining data from human cohorts and through further work on the
animal model. Finally, these findings suggest that elevated PHLDA2
expression might be most harmful in scenarios in which the placenta is
working at maximum capacity, such as in pregnancies subject to prenatal
adversity.
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Fig. 1. Characterisation of the single-copy line BACx1 on a 129 strain
background. (A) QPCR analysis of Phlda2 and Slc22a18 expression in
E14.5 Phlda2+/+BACx1(129) placentae. (B) Fetal wet weights on the 129 genetic
background at E14.5, E16.5 and E18.5. Phlda2+/+BACx1(129) (2×) fetuses
(n=36) were significantly lighter at E18.5, weighing 90.7% of the weight of
their non-transgenic counterparts (P=5.33×10−6). (C) Placental wet weights
on the 129 genetic background. Phlda2+/+BACx1(129) (2×) placentae were
significantly lighter that non-transgenic placentae at each time point.
Numerical data is given in supplementary material Table S1. NS, not
significant (P>0.05), *P<0.05, ***P<0.005.
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than control placentae at E18.5 (94.9±4.1 mg versus 71.5±0.9 mg;
P=8.41×10−8; Fig. 2C). As in the study of Phlda2 loss of function
on the BL6 background, Phlda2–/+(129) fetuses, which lacked the
maternal Phlda2 allele, were not advantaged by the possession of a
larger placenta and weighed the same as their non-transgenic
counterparts at E18.5 (1116.1±19.1 mg versus 1123.3±13.8;
P=0.753; Fig. 2B). These data formally assigned the late fetal
growth restriction phenotype to twofold-elevated expression of
Phlda2 and confirmed that loss of function of Phlda2 does not
induce fetal overgrowth.
Fetal growth restriction due to placental insufficiency is often
asymmetric, with a relative reduction in fetal kidney, liver, pancreas
and lung size but a sparing of the brain. When organ weights of the
four genotypes were compared at E18.5, the brain weights of the
Phlda2+/+BACx1 fetuses were 10% heavier relative to body weight as
compared to the non-transgenic fetuses, suggestive of brain sparing
(Fig. 3A). The lungs and heart were proportionately growth
restricted, whereas the liver and kidney, sites of embryonic Phlda2
expression (Qian et al., 1997), were growth restricted as a proportion
of body weight (Fig. 3A). Brain sparing was similarly apparent in
newborn mice carrying three copies of the transgene
(Phlda2+/+BACx3) examined on the 129 genetic background
(Fig. 3B). Normalising the dose of Phlda2 restored symmetry to the
fetus (Fig. 3A). These data genetically demonstrated that twofold
elevated Phlda2 restricts fetal growth asymmetrically. Moreover,
loss of function of Phlda2 had no significant consequence for these
organ weights, excluding a reciprocal function for Phlda2 in
regulating organ weights.
Catch-up growth is a key feature of extrinsically driven fetal growth
restriction (Saenger et al., 2007). When postnatal weights for line
Phlda2+/+BACx3 were examined from birth (P0) until 4 weeks of age
(P28), pups were born weighing 11% less than their non-transgenic
counterparts (1.25±0.014 g versus 1.41±0.009 g; P=3.29×10−17).
Within 7 days, there was no significant difference in the weights
between transgenic and non-transgenic pups (P=0.147; Fig. 3C).
Placental weight and fetal:placental (F:P) ratios are widely used
as a parameter of placental functional capacity (Fowden et al.,
2009). The F:P ratio for mice of the 129 genetic background at
E18.5 is relatively high, at 16.0±0.23, whereas that of C57BL/6
(BL6) mice is lower, at 12.3±0.18 (Tunster et al., 2012). This
suggests that BL6 placenta might have a greater reserve capacity
than 129 placenta. To investigate whether Phlda2 similarly
restrained fetal growth in the context of a more favourable F:P ratio,
we bred Phlda2+/+BACx1 and Phlda2+/+BACx3 (three copy line) mice
onto the BL6 genetic background for >eight generations. We
observed no difference in fetal weight at E14.5, E16.5 or E18.5
(Fig. 4A) despite transgenic placentae weighing 10-15% less than
non-transgenic placentae at each time point (Fig. 4B). When we
examined F:P ratios, there was a significant difference from normal
at every time point due to the reduction in weight of the placenta but
not the fetus on the BL6 background (Fig. 4C). F:P ratios were also
significantly different from normal at E14.5 and E16.5 on the 129
background. At E18.5, there was no significant difference in F:P
ratio because, at this later time point, both placental and fetal
weights were reduced. This suggests that 129 placentae function at
maximum capacity late in gestation and consequently cannot
compensate for the reduction in capacity induced by elevated
Phlda2, resulting in fetal growth restriction
A reduced junctional zone and loss of placental glycogen have
been linked to fetal growth restriction in several studies (Hitz et al.,
2005; Oh-McGinnis et al., 2011; Withington et al., 2006; Zheng-
Fischhöfer et al., 2007). Furthermore, placental glycogen has been
suggested as an important source of easily utilisable energy to
support late embryonic growth (Coan et al., 2006). In addition to the
difference in F:P ratios, BL6 placentae have a disproportionately
larger junctional zone and significantly greater stores of placental
glycogen than 129 placentae (Tunster et al., 2012). In situ
hybridisation with trophoblast specific protein alpha (Tpbpa), a
marker for the junctional zone (Lescisin et al., 1988), revealed a
reduction of the junctional zone at E14.5 on both the 129 and the
BL6 genetic backgrounds for line Phlda2+/+BACx1 (Fig. 5A). To
establish to what extent elevated Phlda2 compromised glycogen
accumulation on the two genetic backgrounds, a biochemical
determination of glycogen was performed at E14.5, E16.5 and
1187
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Fig. 2. Isolating a causative role for elevated Phlda2 in inducing late
fetal growth restriction (129 strain background). (A) QPCR analysis of
Phlda2 and Slc22a18 expression in E14.5 Phlda2+/+(129) (wild type; non-
transgenic) versus Phlda2–/+BACx1(129) (1×) (double transgenic) from litters
containing all four genotypes. Phlda2 expression was normal in double-
transgenic placenta. (B) E18.5 fetal wet weights for Phlda2+/+(129) (WT),
Phlda2+/+BACx1(129) (BACx1; 2×), Phlda2–/+(129) (KO; 0×) and Phlda2–/+BACx1(129)
(KO & BACx1; 1×) from litters containing all four genotypes on the 129
genetic background. Fetal growth restriction was attenuated in double-
transgenic fetuses. Phlda2–/+(129) (0×) fetuses were similar in weight to
controls. (C) E18.5 placental wet weights for the litters used to generate data
in Fig. 2B. Placental growth restriction was apparent only when Phlda2
expression was elevated (Phlda2+/+BACx1(129)). Phlda2–/+(129) (0×) placentae
were 33% heavier than controls. Numerical data is given in supplementary
material Table S2. NS, not significant (P>0.05), **P<0.01, ***P<0.005.
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E18.5. Twofold expression of Phlda2 induced a 50-60% decrease in
total glycogen on the 129 background and 40-45% decrease on the
BL6 background, relative to the respective non-transgenic
counterparts, at each time point (Fig. 5B,C). A similar reduction was
apparent for the three-copy line at E18.5 on both backgrounds
(Fig. 5B,C). Thus, elevated Phlda2 similarly limited the
accumulation of glycogen on both genetic backgrounds. However,
although the amplitude of the effect was similar, a comparison of the
amount of glycogen stored, expressed either relative to the weight
of the placenta (mg/g) or as a total amount (mg), highlighted a
striking finding. Whereas  glycogen stores were compromised on
both genetic backgrounds by elevated Phlda2, the compromised
BL6 placentae (Phlda2+/+BACx1(BL6)) still contained three times more
glycogen than the genetically uncompromised 129 placentae
(Phlda2+/+(129)) (Fig. 5D-F).
Taken together, these data genetically define a role for elevated
Phlda2 in asymmetrically restricting late fetal growth but suggests
that the growth-restricting properties of Phlda2 manifest only in
unfavourable circumstances in which the placenta is already
functioning at its upper limit to support the growth demands of the
rapidly growing fetus.
DISCUSSION
Elevated expression of the imprinted gene PHLDA2 has been reported
in a number of studies on LBW and fetal growth restriction, but
correlation does not always equal causation. Here, we have
demonstrated, using a mouse model, that twofold elevated expression
of Phlda2 can restrain fetal growth late in gestation. Moreover, we
have also shown that Phlda2-induced growth restriction is
asymmetric, with a relative sparing of the brain alongside rapid
postnatal catch-up growth. However, we did not observe a similar
growth restriction on a different genetic background.
Mouse and human placentae differ substantially not only with
respect to histologically classified lineages but also with respect to
RESEARCH ARTICLE Disease Models & Mechanisms (2014) doi:10.1242/dmm.017079
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gene expression (Carter, 2012). Nonetheless, our data support a causal
role for elevated PHLDA2 in restricting fetal growth in human
pregnancies. In the study by McMinn et al., ~25% of the placentae
from growth-restricted babies showed increased expression of
PHLDA2 (McMinn et al., 2006). Kumar et al. similarly reported
elevated placental PHLDA2 in relation to fetal growth restriction, and
Diplas et al. reported a threefold increase in placental PHLDA2 in
very LBW babies (Kumar et al., 2012; Diplas et al., 2009). These data
suggest that elevated PHLDA2 might be a relatively common cause
of LBW in human populations. Our findings in the mouse model that
Phlda2-induced growth restriction was asymmetric, with relative
sparing of the brain, followed by rapid catch-up growth, is
consequently of significant importance. Human babies with these
characteristics, particularly those with accelerated postnatal weight
gain after in utero growth restriction, have a greatly enhanced risk of
developing type 2 diabetes, obesity and cardiovascular disease
[Barker, 1990; Barker, 1994; Barker, 2004; Barker et al., 2006; Barker
et al., 1991; Barker, 2001; Barker and Medical Research Council,
Environmental Epidemiology Unit (UK), 1992; Lackland et al., 2000;
Lackland et al., 2001]. These diseases are thought to reflect the
programming of metabolic abnormalities in utero in response to
limited nutrient supply acerbated by optimal or even excessive
nutrition after birth. This suggests that babies with elevated placental
PHLDA2 might be at risk of these later-life health complications.
Further work is required to follow up the later-life outcomes for babies
with elevated PHLDA2 and also our transgenic mice to identify the
predictive value of PHLDA2 as a biomarker.
Several human studies suggest that PHLDA2 expression inversely
correlates with birth weight even within normal pregnancies
(Apostolidou et al., 2007; Guo et al., 2008; Lim et al., 2012).
Moreover, in a study of >7000 samples over three cohorts, a
PHLDA2 promoter polymorphism was positively correlated with
birth weight (Ishida et al., 2012). An inverse correlation with LBW
was not reproduced in two other studies (Lambertini et al., 2012;
1189
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growth restriction. (A) In situ hybridisation of
Tpbpa riboprobe to E14.5 sections from
Phlda2+/+(129) and Phlda2+/+BACx1(129) (2×)
placenta in comparison to the same genotypes
on the BL6 genetic background. Scale bars: 
200 μm. (B) Biochemical determination of
glycogen at E14.5, E16.5 and E18.5 for
Phlda2+/+BACx1 and at E18.5 for Phlda2+/+BACx3
(4×) on the 129 background expressed as a
percentage of values in non-transgenic
placenta. (C) Biochemical determination of
glycogen at E14.5, E16.5 and E18.5 for
Phlda2+/+BACx1 and at E18.5 for Phlda2+/+BACx3
on the BL6 background expressed as a
percentage of values in control placenta.
(D) 129 glycogen data from panel B expressed
as mg/g of placenta. (E) BL6 glycogen data
from panel C expressed as mg/g of placenta.
(F) Comparison of total glycogen stored in
E18.5 placenta on the 129 versus BL6
background. Compromised (Phlda2
overexpression) BL6 placentae contain three
times more glycogen than that found in the
uncompromised (Phlda2 wild-type expression)
129 placentae. Numerical data is given in
supplementary material Table S5. **P<0.01,
***P<0.005.
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Lewis et al., 2012), although these studies only looked at ~100
samples. In our previous investigation of PHLDA2 expression in
placentae from the Southampton Women’s Study, we did not find a
significant inverse association between placental PHLDA2 and birth
weight, but we did observe a slowdown in fetal femur growth late
in gestation and a significant loss of bone density at age 4 years
(Lewis et al., 2012). In this current study, we found that the growth-
restricting properties of Phlda2 were apparent on the 129 and not
the BL6 genetic background, despite similar proportional reductions
in placental weight and glycogen stores. Both the human data and
our mouse data can be reconciled if elevated PHLDA2 only restricts
fetal growth under certain circumstances, i.e. when the placenta is
working at maximum capacity or when other factors, such as
environmental exposures, limit placental capacity extrinsically.
LBW is particularly prevalent in populations under severe
socioeconomic stress; this could be due to a multitude of factors
including poor diet, maternal stress and smoking. Human placental
PHLDA2 has been reported to be upregulated in response to
maternal smoking; additionally, in an experimental rat model, both
maternal calorie restriction and alcohol were found to result in
significantly upregulated placental Phlda2 (Bruchova et al., 2010;
Shukla et al., 2011). We did not identify a correlation between
placental PHLDA2 expression and maternal lifestyle in our
relatively small study (Lewis et al., 2012), but it might be pertinent
to further explore the data on PHLDA2 both with respect to
asymmetry and catch-up growth while taking into account the
degree of prenatal adversity experienced by the mother.
In summary, our work has identified a causative role for elevated
Phlda2 in inducing asymmetrical late fetal growth restriction.
Importantly, our work also suggests that elevated Phlda2 might be
more harmful in scenarios where the placenta is working at maximum
capacity, such as in pregnancies subject to prenatal adversity.
MATERIALS AND METHODS
Mouse strains and genotyping
Animal studies and breeding were approved by the Universities of Cardiff
ethical committee and performed under a UK Home Office project licence
(RMJ). All mice were housed together in one room throughout the study on
a 12-hour light-dark cycle with lights coming on at 06.00 hour and a
temperature range of 21±2°C with free access to water (tap water) and
standard chow. The Phlda2 transgenic lines Phlda2+/+BACx1(129) (previously
Tg10-10) and Phlda2+/+BACx3(129) (previously Tg10-15) were bred for >eight
generations onto either the C57BL6 (Harlan, BL6) or the 129S2/SvHsd
(Harlan, 129) strain backgrounds for phenotypic assessment. The Phlda2
targeted allele was either maintained by paternal transmission on the BL6
background or crossed into the 129 background for >eight generations.
Weighing studies and biochemical determination of placental
glycogen concentration
Fetal and placental wet weights were taken at the stated time points after a
discernible plug. Genotyping data was obtained from yolk sac DNA as
previously described (Frank et al., 2002; John et al., 2001). Glycogen was
extracted from whole placenta, and resuspended in 1 ml of H2O and assayed
according to the method of Lo et al. (Lo et al., 1970) at a dilution of 1 in 2
(129) or 1 in 10 (BL6).
Quantitative RNA analysis
Quantitative PCR of reverse-transcribed RNA (QRT-PCR) was performed and
analysed as described (Schmittgen and Livak, 2008; Tunster et al., 2010).
Statistical analyses
Statistical significance (probability values) was determined using the
Student’s t-test (two-tailed distribution and two-sample unequal variance) or
the Mann-Whitney U-test.
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